Skip to main content

Research Repository

Advanced Search

Dr EMMA WILMOT's Outputs (8)

Patient‐reported outcomes in studies of diabetes technology: What matters (2024)
Journal Article
Liarakos, A. L., Crabtree, T. S., & Wilmot, E. G. (2024). Patient‐reported outcomes in studies of diabetes technology: What matters. Diabetes, Obesity and Metabolism, 26(S7), 59-73. https://doi.org/10.1111/dom.15858

In recent years, diabetes technologies have revolutionized the care of people with type1 diabetes (T1D). Emerging evidence suggests that people with type 2 diabetes (T2D) canexperience similar benefits from these advances in technology. While glycaem... Read More about Patient‐reported outcomes in studies of diabetes technology: What matters.

Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes (2024)
Journal Article
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., & Sherr, J. L. (2024). Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology and Therapeutics, 26(8), 514-525. https://doi.org/10.1089/dia.2023.0578

Background:

The Omnipod® 5 Automated Insulin Delivery System was associated with favorable glycemic outcomes for people with type 1 diabetes (T1D) in two pivotal clinical trials. Real-world evidence is needed to explore effectiveness in nonstudy... Read More about Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.

The use of technology in type 2 diabetes and prediabetes: a narrative review (2024)
Journal Article
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024). The use of technology in type 2 diabetes and prediabetes: a narrative review. Diabetologia, 67(10), 2059-2074. https://doi.org/10.1007/s00125-024-06203-7

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of... Read More about The use of technology in type 2 diabetes and prediabetes: a narrative review.

Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring (2024)
Journal Article
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2024). Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, https://doi.org/10.1177/19322968241250357

Continuous glucose monitoring (CGM) has been shown to improve glycemic control and self-monitoring, as well as to reduce the risk of hypoglycemia. Integrated CGM (iCGM) FDA-cleared systems with published performance data are established nonadjunctive... Read More about Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring.

Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis (2024)
Journal Article
Mader, J. K., Fornengo, R., Hassoun, A., Heinemann, L., Kulzer, B., Monica, M., Nguyen, T., Sieber, J., Renard, E., Reznik, Y., Rys, P., Stozek, A., & Wilmot, E. G. (2024). Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis. Diabetes Technology and Therapeutics, 26(5), 351-362. https://doi.org/10.1089/dia.2023.0491

Background: Lipohypertrophy is a common complication in patients with diabetes receiving insulin therapy. There is a lack of consensus regarding how much lipohypertrophy affects diabetes management. Our study aimed to assess the potential correlation... Read More about Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis.

Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study (2024)
Journal Article
Liarakos, A. L., Hasan, N., Crabtree, T. S. J., Leelarathna, L., Hammond, P., Hussain, S., Haq, M., Aslam, A., Gatdula, E., Gibb, F. W., Lumb, A., Bull, K., Chinnasamy, E., Carrieri, G., Williams, D. M., Choudhary, P., Ryder, R. E. J., & Wilmot, E. G. (2024). Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study. Diabetes Research and Clinical Practice, 209, Article 111597. https://doi.org/10.1016/j.diabres.2024.111597

Aims
To evaluate real-world outcomes in people with Type 1 Diabetes (PwT1D) initiated on Omnipod DASH® Insulin Management System

Methods
Anonymized clinical data were submitted to a secure web-based tool within the National Health Service networ... Read More about Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.

Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation (2024)
Journal Article
Ssemmondo, E., Deshmukh, H., Wilmot, E. G., Adeleke, K. A., Shah, N., Walton, C., Barnes, D., Ryder, R. E. J., & Sathyapalan, T. (2024). Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation. Diabetes, Obesity and Metabolism, 26(4), 1340-1345. https://doi.org/10.1111/dom.15435

AbstractAimTo understand the effect of intermittently scanned continuous glucose monitoring (isCGM) in people with diabetes with a ‘psychosocial’ indication for access.MethodsThe study utilized baseline and follow‐up data from the Association of Brit... Read More about Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation.